Direct thrombin inhibitors and factor Xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 7, 2013, Pages 967-973

  Olah, Zsolt ^a   Szarvas, Mariann ^a   Bereczky, Zsuzsanna ^a   Kerenyi, Adrienne ^a   Kappelmayer, Janos ^a   Boda, Zoltan ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; CHONDROITIN SULFATE; DANAPAROID; DERMATAN SULFATE; ENOXAPARIN; FONDAPARINUX; HEPARAN SULFATE; HIRUDIN DERIVATIVE; LEPIRUDIN; LUPUS ANTICOAGULANT; PIPECOLIC ACID DERIVATIVE; POLYSACCHARIDE; RECOMBINANT PROTEIN; THROMBIN;

ARTICLE; BLOOD; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; LABORATORY DIAGNOSIS; MASS SCREENING; METHODOLOGY; PROTHROMBIN TIME;

ANTICOAGULANTS; ANTITHROMBINS; CHONDROITIN SULFATES; DERMATAN SULFATE; ENOXAPARIN; FACTOR XA; FALSE POSITIVE REACTIONS; HEPARITIN SULFATE; HIRUDINS; HUMANS; LUPUS COAGULATION INHIBITOR; MASS SCREENING; PIPECOLIC ACIDS; POLYSACCHARIDES; PROTHROMBIN TIME; RECOMBINANT PROTEINS; THROMBIN;

EID: 84879630205     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0236-OA     Document Type: Article

References (23)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
2. Sangle NA, Smock KJ. Antiphospholipid antibody syndrome. Arch Pathol Lab Med. 2011;135(9):1092-1096.
3. Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus: comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost. 1996; 76(6):916-924.
4. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827-1832.
5. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update: on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74(4):1185-1190.
6. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7(10):1737-1740.
7. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost. 2001;86(1):83-91.
8. Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol. 1994;87(1):94-99.
9. Devreese KMJ. Evaluation of a new commercial dilute prothrombin time in the diagnosis of lupus anticoagulants. Thromb Res. 2008;123(2):404-411.
10. Nakai K, Wada H, Nakatani K, et al. Usefulness of a diluted prothrombin time for accurately diagnosing antiphospholipid syndrome. Vasc Dis Prev. 2009; 6(1):25-29.
11. Linkins L, Dans AL, Moores LK, et al. Treatment and prevention of heparininduced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):495S-530S.
12. Moffat KA, Ledford-Kraemer MR, Plumhoff EA, et al. Are laboratories following published recommendations for lupus anticoagulant testing? Thromb Haemost. 2009;101(1):178-184.
13. Jennings I, Kitchen S, Kitchen DP, Woods TAL, Walker D. ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories? J Thromb Haemost. 2011;9(10):2117-2119.
14. Galli M, Borrelli G, Jacobsen EM, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood. 2007;110(4):1178-1183.
15. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human b2-glycoprotein I. Thromb Haemost. 1999;81(6):929-934.
16. Jennings I, Mackie I, Arnout J, Preston FE. Lupus anticoagulant testing using plasma spiked with monoclonal antibodies: performance in the UK NEQAS proficiency testing programme. J Thromb Haemost. 2004;2(12):2178-2184.
17. Genzen JR, Miller JL. Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing. Am J Clin Pathol. 2005; 124(4):586-593.
18. Gosselin RC, King JH, Janatpur KA, Dager WH, Larkin EC, Owings JT. Effects of pentasaccharide (Fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med. 2004;128(10):1142-1145.
19. Liestl S, Jacobsen EM, Wislff F. Dilute prothrombin time-based lupus ratio test: integrated LA testing with recombinant tissue thromboplastin. Thromb Res. 2002;105(2):177-182.
20. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):24S-43S.
21. Depasse F, Gerotziafas GT, Busson J, Van Dreden P, Samama MM. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. J Thromb Haemost. 2004;2(2):346-348.
22. Merriman E, Kaplan Z, Butler J, Malan E, Gan E, Tran H. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost. 2011;105(2):385-386.
23. Van Os GMA, de Laat B, Kamphuisen PW, Meijers JCM, de Groot PHG. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost. 2011;9(8):1657-1659.